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Should all patients with adrenal insufficiency or a subgroup of patients with pre-diabetes be 
treated with dual-release hydrocortisone ? 
 
Guarnotta et al. compare the effects of dual-release (DR) hydrocortisone 36 months’ treatment in 13 
patients with primary adrenal insufficiency and 36 with secondary adrenal insufficiency, compared 
to conventional glucocorticoid treatment. A retrospective evaluation was conducted on the effects 
of 36 months of DR hydrocortisone therapy on visceral adiposity, insulin secretion and insulin 
sensitivity. Forty-nine patients with adrenal insufficiency were recruited. They had been on stable 
conventional glucocorticoid treatment before entering the study and underwent clinical and 
metabolic evaluation at baseline (during conventional glucocorticoid treatment) and at 12, 24 and 
36 months after switching to DR hydrocortisone,  
DR hydrocortisone is a formulation that consists of an extended-release core surrounded by an 
immediate release coating. DR hydrocortisone absorption is rapid (17-20 min for the 20 mg tablet in 
the fasting state) and can induce an adequate increase in morning cortisol levels with a peak 
concentration time similar to the one observed with conventional hydrocortisone. However, it 
produces a more gradual decline in cortisol concentrations than conventional hydrocortisone. DR 
hydrocortisone was developed to obtain a more physiological circadian cortisol exposure time after 
a once daily administration (1). 
Although a lot of work has been done  to optimize glucocorticoid treatment with more physiological 
formulations of hydrocortisone in the last two decades, there has been no consistent evidence that 
more physiological replacement of corticosteroid therapy is superior to the conventional once, twice 
or thrice daily dosages of short-acting corticosteroids. However, previous studies did not carefully 
measure insulin sensitivity and secretion during DR-hydrocortisone. 
Guarnotta et al. report that long-term DR-hydrocortisone is associated with an improvement in 
insulin secretion and sensitivity in patients with impaired fasting glucose and/or impaired glucose 
tolerance. The investigators also report an improvement of other parameters (body mass index, 
waist circumference, glycated haemoglobin and high-density-lipoprotein-cholesterol) in the entire 
cohort (including those patients without pre-diabetes).  
As reported by the Authors, the retrospective design is the main limitation to the study since a 
cross-over study design would have been preferable for the assessment and verification of the 
effects of DR hydrocortisone. The small sample size is another principal limitation.  
The cohort of patients studied by Guarnotta et al. is too heterogeneous to draw a definitive 
conclusion on the role of DR-hydrocortisone therapy on glucose homeostasis and insulin sensitivity, 
but these findings justify for future study on the topic. Future studies should contain adequate 
numbers of patients with primary and secondary hypoadrenalism. 
It is well known that exogenous glucocorticoids affect glucose metabolism, and induce  peripheral 
insulin resistance by impairing insulin signaling. This will lead to decreased glucose disposal and 
increased glucose production. Moreover, since β-pancreatic cells undergo several adaptations  
hyperinsulinaemia may occur (2).  
As regards the effects of long-term glucocorticoid replacement therapy on glucose metabolism in 
patients with hypoadrenalism data are sparse and at times contradictory (3,4).  
Previous studies on patients with primary hypoadrenalism reported that high doses of conventional 
glucocorticoids (e.g. hydrocortisone 30 mg daily or cortisone acetate 37.5 mg daily) showed 
increased glucose levels and (Homeostasis Model Assessment) HOMA index, compared to controls 
(5). Furthermore, a study conducted on patients with primary adrenal insufficiency and type 1 
diabetes mellitus, showed higher insulin requirements (about 35%) were needed compared to 
patients with type 1 diabetes mellitus (6).  
Due to the insufficient number and contradictory data of studies on patients with secondary 
hypoadrenalism during conventional glucocorticoid replacement therapy, no definitive conclusion 
can be made as to the role of glucocorticoids on glucose metabolism (4). One study (7) reported a 
reduced prevalence in impaired glucose tolerance and diabetes during hydrocortisone replacement 
with 20 mg/daily, while others found no difference in fasting glucose, insulin levels or glycated 
haemoglobin after a hydrocortisone reduction from 30 to 15 mg daily (8-10).  
Unlike Guarnotta et al, insulin sensitivity and secretion have not been carefully measured in these 
studies  
Most of the previous published studies of DR-hydrocortisone focused on primary adrenal 
insufficiency, and the data for the effects of DR-hydrocortisone on secondary adrenal insufficiency 
are scanty. At least four clinical studies have assessed the effect of DR-hydrocortisone on metabolic 
parameters in patients with primary adrenal insufficiency. In aggregate, these studies demonstrate 
that DR-hydrocortisone significantly reduces body weight and improves glucose metabolism 
compared to conventional hydrocortisone replacement therapy and without significant differential 
effects between normoglycemic patients and diabetic patients (11-14). Therefore, in this subgroup 
of patients, the suggestion by Guarnotta et al. to treat with DR-hydrocortisone only pre-diabetes 
patients might not be entirely shareable, since other studies indicate that all the patients with 
primary adrenal insufficiency should benefit from DR-hydrocortisone therapy. 
There have been three studies concerning the metabolic effects of DR-hydrocortisone therapy in 
patients with secondary hypoadrenalism. Quinkler et al. (12) studied a heterogeneous group of 
hypoadrenal patients (including 18 secondary adrenal insufficient patients) and reported that  DR-
hydrocortisone decreased glycated haemoglobin compared with conventional treatment in all 
patients, without specifying  the effects of DR-hydrocortisone on  secondary forms. Mongioi et al. 
(14) reported that a cohort of 9 patients with secondary hypoadrenalism showed no significant 
change in fasting glucose, serum insulin levels, serum glycated haemoglobin and HOMA index 
after 12 months of DR hydrocortisone treatment. Frara et al. (15) reported no significant change in 
serum glycated haemoglobin and lipid parameters in a cohort of 14 patients with secondary 
hypoadrenalism after 24 months of DR-hydrocortisone therapy. 
In secondary hypoadrenalism, other pituitary deficiencies or replacement therapies are to be 
considered as an additional risk factor for metabolic disorders. In particular, insulin resistance is a 
frequent corollary of growth hormone (GH) replacement therapy and glucocorticoid tissue exposure 
can be increased during recombinant human GH replacement therapy owing to the effect of GH on 
11β-hydroxysteroid dehydrogenases type 1 (4). In the study by Guarnotta et al, as in previous 
studies, GH-deficiency patients underwent somatotropin treatment that might influence insulin 
secretion and sensitivity.  
The study by Guarnotta et al. suggests that DR-hydrocortisone therapy might be superior to 
conventional glucorticoid replacement therapy for patients with pre-diabetes. Larger, case-
controlled randomized studies of patients with both primary and secondary forms are required to 
confirm this novel and clinically significant finding. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Johannsson G, Bergthorsdottir R, Nilsson AG, Lennernas H, Hedner T, Skrtic S. Improving 
glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a 
pharmacokinetic study. Eur J Endocrinol 2009; 161:119–130 
2. Rafacho A, Ortsater H, Nadal A, Quesada I. Glucocorticoid treatment and endocrine pancreas 
function: implications for glucose homeostasis, insulin resistance and diabetes. Eur J Endocrinol. 
2014;223:R49‐R62. 
3. Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, Husebye ES, 
Merke DP, Murad MH, Stratakis CA, Torpy DJ. Diagnosis and Treatment of Primary Adrenal 
Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 
2016;101:364-389. 
4. Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R,  Samuels MH. 
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice 
Guideline. J Clin Endocrinol Metab. 2016; 101: 3888-3921. 
5. Giordano R, Marzotti S, Balbo M, Romagnoli S, Marinazzo E, Berardelli R, Migliaretti G, Benso 
A, Falorni A, Ghigo E, Arvat E. Metabolic and cardiovascular profile in patients with Addison’s 
disease under conventional glucocyorticoid replacement. J Endocrinolol Invest 2009; 32: 917-923. 
6. Elbelt U, Hahner S, Allolio B. Altered insulin requirement in patients with type 1 diabetes and 
primary adrenal insufficiency receiving standard glucocorticoid replacement therapy. Eur J 
Endocrinol. 2009;160:919‐924. 
7. McConnell EM, Bell PM, Hadden DR, McCance DR, Sheridan B, Atkinson AB. Prevalence of 
diabetes and impaired glucose tolerance in adult hypopituitarism on low dose oral hydrocortisone 
replacement therapy. Clin Endocrinol (Oxf). 2001;54:593-599. 
8.Segerlantz M, Bramnert M, Thomasson R, Manhem P, Laurila E, Groop LC. Effects of morning 
cortisol replacement on glucose and lipid metabolism in GH-treated subjects. Eur J Endocrinol. 
2004;151:701-707. 
9. Filipsson H, Monson JP, Koltowska-Häggström M, Mattsson A, Johannsson G. The impact of 
glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary 
patients. J Clin Endocrinol Metab. 2006;91:3954-3961. 
10. Suliman AM, Freaney R, Smith TP, McBrinn Y, Murray B, McKenna TJ. The impact of 
different glucocorticoid replacement schedules on bone turnover and insulin sensitivity in patients 
with adrenal insufficiency. Clin Endocrinol (Oxf). 2003;59:380-387. 
11. Johannsson G, Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B, Engström BE, 
Olsson T, Ragnarsson O, Ryberg M, Wahlberg J, Biller BM, Monson JP, Stewart PM, Lennernäs H, 
Skrtic S. Improved cortisol exposure time profile and outcome in patients with adrenal 
insufficiency: a prospective randomized trial of a novel hydrocortisone dual release formulation. J 
Clin Endocrinol Metab. 2012; 97: 473–481. 
12. Quinkler M, Miodini Nilsen R, Zopf K, Ventz M, Oksnes M. Modified-release hydrocortisone 
decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur J 
Endocrinol. 2015; 172: 619-626. 
13. Giordano R, Guaraldi F, Marinazzo E, Fumarola F, Rampino A, Berardelli R, Karamouzis I, 
Lucchiari M, Manetta T, Mengozzi G, Arvat E, Ghigo E. Improvement of anthropometric and 
metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in 
patients with Addison's disease. Endocrine 2016; 51: 360-368. 
14. Mongioì LM, Condorelli RA, La Vignera S, Calogero AE. Dual-release hydrocortisone 
treatment: glycometabolic profile and health-related quality of life. Endocr Connect. 2018;7:211-
219. 
15. Frara S, Chiloiro S, Porcelli T, Giampietro A, Mazziotti G, De Marinis L, Giustina A. Bone 
safety of dual-release hydrocortisone in patients with hypopituitarism. Endocrine 2018 Jan 8. doi: 
10.1007/s12020-017-1512-1. 
